1888PressRelease.com
1888 PressRelease Home Sign In Register About Us Sitemap
  
09
Apr
2009

Worldwide Market for Drug-Eluting, Bare and Other Coronary Stents, 2008-2017, New Report (MedMarket Diligence)

Coronary artery disease is addressed by a range alternative treatment methodologies; percutaneous intervention with or without stenting, coronary artery bypass grafting alternatives and other options, but stents represent the fastest growing option.


(1888PressRelease) April 09, 2009 - MedMarket Diligence, drawing on its coverage of coronary stents through the previously published MedMarkets publication and leveraging its expertise in assessing advanced medical technologies markets, is publishing its 2009 report, "Worldwide Market for Drug-Eluting, Bare, Bioresorbable and Other Coronary Stents, 2008-2017."

"The coronary stents market is extremely dynamic by virtue of the relative nascency of the market, particularly for drug-eluting stents (DES; first introduced in 2003). Rapidly growing to a $5 billion market initially dominated by leader Johnson & Johnson's CYPHER, then Boston Scientific's TAXUS, drug-eluting stents arguably represent a successful challenge to coronary artery bypass grafting in the treatment of coronary artery disease" says Patrick Driscoll, President of MedMarket Diligence.

The successes of J&J and Boston Scientific have spurred a stream of newcomers with DES products and other stent types to the market. A range of new stents, with different constructions, material types (including bioabsorbable), coating types and other variations are now at various stages of introduction to the market.

MedMarket Diligence's report #C245, "Worldwide Market for Drug-Eluting, Bare and Other Coronary Stents, 2008-2017," details the worldwide market for the use of coronary stents in the treatment of coronary artery disease. The report assesses the treatment of coronary artery disease by alternative treatment methodologies (percutaneous intervention with or without stenting, coronary artery bypass grafting alternatives and other medical/surgical treatment options), with estimated current/forecast caseload across treatment types. The report details currently approved coronary stents, providing data on current and forecast impact on the market. The report also details the current state of product development in bare stents, drug-coated or drug-eluting stents and bioabsorbable stents in coronary applications and details the products under development, the anticipated timeline and impact of their market introduction. The report assesses the current and ten-year forecast global market for coronary stents, with segmentation by U.S., Europe, Asia/Pacific and Rest of World. The report provides competitor market shares by these geographic regions. The leading and key emerging coronary stent manufacturers are profiled with current product offerings, development status and market strengths/advantages.

The report is being released in April 2009 and is detailed at http://www.mediligence.com/rpt/rpt-c245.htm. The report may be advance ordered (with discount) online at http://www.mediligence.com/store/page30.html or may be ordered via order form, http://www.mediligence.com/order_forms/c245_order.pdf.

###
 

Other Related Press Releases

Kpi-insight Consulting To Feature In CEO Today Magazine April Edition by Kpi-insight Consulting

GlaxoSmithKline Awards Ten Healthcare Nonprofits With $40,000 Each In Funding by Furia Rubel Communications, Inc.

Worldwide Market for Drug-Eluting, Bare and Other Coronary Stents, 2008-2017, New Report (MedMarket Diligence) by Medmarket Diligence Llc

Contact Information

Patrick Driscoll

Medmarket Diligence Llc

92610

Voice: 1-949-859-3401

Visit our Site

Press Release Tools